Effects of Ambrisentan in a Patient Affected by Combined Pulmonary Fibrosis and Emphysema and by Severe Pulmonary Hypertension: Clinical, Functional, and Biomolecular Findings

[1]  R. Savino,et al.  Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF‐κB in lung cancer and in normal pulmonary tissues , 2013, Cell proliferation.

[2]  R. Savino,et al.  Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non‐small lung cancer cells , 2012, Cell proliferation.

[3]  R. Savino,et al.  Simultaneous extraction and rapid visualization of peptidomic and lipidomic body fluids fingerprints using mesoporous aluminosilicate and MALDI‐TOF MS , 2012, Proteomics.

[4]  C. DeSouza,et al.  Elevated endothelin-1 vasoconstrictor tone in prehypertensive adults. , 2012, The Canadian journal of cardiology.

[5]  M. Reynaud‐Gaubert,et al.  Endothelin receptor antagonists -- their role in pulmonary medicine. , 2011, Revue des maladies respiratoires.

[6]  C. Derk,et al.  Endothelin receptor antagonists as disease modifiers in systemic sclerosis. , 2011, Inflammation & allergy drug targets.

[7]  V. Cottin,et al.  Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. , 2011, Arthritis and rheumatism.

[8]  D. Abraham,et al.  Endothelin in pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.

[9]  M. Cazzola,et al.  Effects of Budesonide on P38 MAPK Activation, Apoptosis and IL-8 Secretion, Induced by TNF-α and Haemophilus Influenzae in Human Bronchial Epithelial Cells , 2010 .

[10]  T. Suarez,et al.  Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. , 2009, Chest.

[11]  V. Cottin,et al.  The syndrome of combined pulmonary fibrosis and emphysema. , 2009, Chest.

[12]  M. Humbert,et al.  Combined Pulmonary Fibrosis and Emphysema with Associated Pulmonary Hypertension: Characteristics and Prognostic Determinants. , 2009, ATS 2009.

[13]  R. Savino,et al.  Interleukin‐6 receptor superantagonist Sant7 inhibits TGF‐β‐induced proliferation of human lung fibroblasts , 2008, Cell proliferation.

[14]  J. Behr,et al.  Pulmonary hypertension in interstitial lung disease , 2008, European Respiratory Journal.

[15]  U. Galderisi,et al.  Effects of TGF‐β and glucocorticoids on map kinase phosphorylation, IL‐6/IL‐11 secretion and cell proliferation in primary cultures of human lung fibroblasts , 2007 .

[16]  U. Galderisi,et al.  Effects of TGF-beta and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. , 2007, Journal of cellular physiology.

[17]  U. Galderisi,et al.  Endothelin‐1 induces proliferation of human lung fibroblasts and IL‐11 secretion through an ETA receptor‐dependent activation of map kinases , 2005, Journal of cellular biochemistry.

[18]  P. Brillet,et al.  Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity , 2005, European Respiratory Journal.

[19]  T. Raedle-Hurst,et al.  Endothelin‐1‐induced proliferation of human endothelial cells depends on activation of K+ channels and Ca2+ influx , 2005 .

[20]  T. Raedle-Hurst,et al.  Endothelin-1-induced proliferation of human endothelial cells depends on activation of K+ channels and Ca+ influx. , 2005, Acta physiologica Scandinavica.

[21]  G. Cuda,et al.  Effects of hydrogen peroxide on MAPK activation, IL‐8 production and cell viability in primary cultures of human bronchial epithelial cells , 2004, Journal of cellular biochemistry.

[22]  A. Filippelli,et al.  Endothelin‐1 increases cholinergic nerve‐mediated contraction of human bronchi via tachykinin synthesis induction , 2001, British journal of pharmacology.

[23]  A. Filippelli,et al.  Endothelin-1 induced bronchial hyperresponsiveness in the rabbit: an ETA receptor-mediated phenomenon , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.